See more : Pharmarise Holdings Corporation (2796.T) Income Statement Analysis – Financial Results
Complete financial analysis of Calidi Biotherapeutics, Inc. (CLDI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calidi Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Great Wall Motor Company Limited (2333.HK) Income Statement Analysis – Financial Results
- EarthRenew Inc. (VVIVF) Income Statement Analysis – Financial Results
- Route Mobile Limited (ROUTE.BO) Income Statement Analysis – Financial Results
- Takasago International Corporation (4914.T) Income Statement Analysis – Financial Results
- MediaTechnics Corporation (MEDT) Income Statement Analysis – Financial Results
Calidi Biotherapeutics, Inc. (CLDI)
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 45.00K | 449.00K | 0.00 |
| Cost of Revenue | 1.26M | 274.00K | 94.00K | 0.00 |
| Gross Profit | -1.26M | -229.00K | 355.00K | 0.00 |
| Gross Profit Ratio | 0.00% | -508.89% | 79.06% | 0.00% |
| Research & Development | 13.01M | 7.26M | 4.67M | 3.18M |
| General & Administrative | 15.98M | 15.90M | 6.16M | 3.59M |
| Selling & Marketing | 0.00 | -260.00K | -4.38M | 0.00 |
| SG&A | 15.98M | 15.64M | 1.78M | 3.59M |
| Other Expenses | 0.00 | -5.00K | 9.00K | 4.00K |
| Operating Expenses | 28.99M | 22.90M | 1.78M | 6.77M |
| Cost & Expenses | 28.99M | 23.17M | 1.78M | 6.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.07M | 158.00K | 614.00K | 163.00K |
| Depreciation & Amortization | 1.26M | 260.00K | 153.00K | 117.00K |
| EBITDA | -27.58M | -25.00M | -9.45M | -6.65M |
| EBITDA Ratio | 0.00% | -50,817.78% | -396.82% | 0.00% |
| Operating Income | -28.99M | -23.13M | -1.78M | -6.77M |
| Operating Income Ratio | 0.00% | -51,395.56% | -396.82% | 0.00% |
| Total Other Income/Expenses | -208.00K | -2.29M | -440.00K | -1.16M |
| Income Before Tax | -29.20M | -25.42M | 3.39M | -7.93M |
| Income Before Tax Ratio | 0.00% | -56,480.00% | 754.29% | 0.00% |
| Income Tax Expense | 16.00K | 11.00K | 11.00K | 4.00K |
| Net Income | -29.22M | -25.43M | 3.39M | -7.94M |
| Net Income Ratio | 0.00% | -56,504.44% | 754.29% | 0.00% |
| EPS | -1.73 | -29.90 | 1.18 | -0.22 |
| EPS Diluted | -17.30 | -29.90 | 1.18 | -0.22 |
| Weighted Avg Shares Out | 16.89M | 850.50K | 2.88M | 35.91M |
| Weighted Avg Shares Out (Dil) | 1.69M | 850.50K | 2.88M | 35.91M |
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
Source: https://incomestatements.info
Category: Stock Reports